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 Summary
Purpose: The linkage of human T-cell leukemia virus type 
1 (HTLV-1) to fatal diseases is a well known fact for many 
years. However, there has been no significant progress in the 
field of the treatment that can lead to the development of a 
successful vaccine. Furthermore, there are no means of as-
sessing the risk of disease and its prognosis in the infected 
people.
Methods: The current study has taken the cognizance of the 
importance of host’s immune response in reducing the risk of 
infectious diseases to carry out immunoinformatics driven 
epitope screening strategy of vaccine candidates against 
HTLV-1. In this study, a genetic variability and HLA distri-
bution analysis among the documented HTLV-1 genotypes 
I, II, III, IV, V & VI was performed to ensure the coverage 
of the vast majority of population, where vaccine would be 
employed. The meticulous screening of effective dominant 
immunogens was done with the help of ABCPred and Im-
mune Epitope Database.
Results: The results showed that the identified epitopes might 
be protective immunogens with high conservancy and poten-
tial of inducing both protective neutralizing antibodies and T-
cell responses. The peptides “PSQLPPTAPPLLPHSNLDHI”, 
“PCPNLVAYSSYHATY”, and “YHATYSLYLF”, were 100% 
conserved among different isolates from far and wide separat-
ed countries, suggesting negligible antigenic drift in HTLV-1.
Conclusions: Overall, the mentioned epitopes are soluble, 
non-toxic suitable candidates for the development of vac-
cine against HTLV-1 and warrant further investigation and 
experimental validation.
Key words: HTLV-1, immunity, immunoinformatics, onco-
genic virus, peptide vaccine
Introduction
 HTLV-1 belongs to delta retrovirus family and 
other members of this family are simian T-lympho-
trophic virus type 1 (STLV-1) and bovine leukemia 
virus (BLV) [1]. HTLV-1 was first reported in a cell 
line derived from a patient with cutaneous T-cell 
lymphoma in 1980 [2]. The symptoms of HTLV-1 
infection do not appear in the majority of people, 
whereas in some people it causes severe problems 
like neoplastic diseases: Adult T-cell Lymphoma 
(ATL), Cutaneous T-cell Lymphoma [3], inflamma-
tory syndromes: HAM/TSP [4], uveitis [5] and op-
portunistic infections: dermatitis, lymphadentis, 
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Sjogren’s syndrome [6]. ATL and HAM/TSP are the 
most predominant among them. ATL has 5 different 
clinical stages: asymptomatic carrier state, preleu-
kemic state, chronic/smoldering ATL, lymphoma 
type ATL and acute ATL [7]. HTLV-I infects T-cells, 
B-cells, dendritic cells, monocytes, and endothelial 
cells equally, yet the virus has preferential tropism 
for CD4 T-cells [8]. HTLV-1, a single-stranded dip-
loid RNA virus, is 9,030–9,040 nucleotides long 
and contains two flanking long terminal repeat 
(LTR) sequences [9] and is packaged in the viral 
core with the viral nucleocapsid protein (p15 NC). 
NC is enclosed in capsid (p24 CA) and matrix (p19 
MA) proteins. Similar to the other retroviruses, the 
HTLV-1 genome encodes the structural proteins 
‘Gag’ (NC, CA, and MA) and ‘Env’, and the enzymat-
ic ‘Pol’ proteins RT, Rnase H (RH), integrase (IN), 
and protease. The env gene encodes two subunit 
proteins: (SU) gp46 and transmembrane (TM) gp21 
[10]. The gp46 confers cell receptor-binding activ-
ity. The fusion of receptor protein is performed by 
gp21. HTLV-I ‘Env’ proteins are genetically highly 
conserved among isolates, with very low variability 
(1 to 8%) within their amino acid sequences [11,12]. 
On the other hand, the cellular entry of HTLV-1 
involves three host cell surface proteins: glucose 
transporter 1 (GLUT1), neuropilin-1 (NRP-1) and 
heparan sulfate proteoglycans (HSPG) [13], lead-
ing to a multi-receptor model host entry for HTLV-
1 [14,15]. The CTD of HTLV-1 SU interacts with 
HSPGs during the initial attachment phase. This 
improves the possibility and strength of binding 
of HTLV-1 SU with NRP-1. The binding of HTLV-I 
SU to NRP-1 leads to a conformational change, re-
sulting in exposure of the GLUT1- binding domain. 
Finally, the interaction of SU with GLUT1 activates 
the translocation of TM gp21 that contributes in 
the fusion mechanism [1]. HTLV-1 virus has six 
known genotypes (HTLV-1a-g), distributed world-
wide [3]. 
 Comprehensive knowledge of the adaptive im-
mune system is required for the development of 
epitope-based vaccines. TH cells and TC cells can 
recognize antigen when bound with major histo-
compatibility Complex (MHC) class II and I mol-
ecule, respectively [15,16]. MHC is a membrane 
glycoprotein. In humans, it is also known as the 
human leukocyte antigen (HLA) and is extremely 
polymorphic in nature. The HLA molecules may 
bind to an array of antigenic linear epitopes derived 
from antigen processing, which initiate an immune 
response. However, HLA binding alone does not en-
Figure 1. Schematic representation of the entire methodology adopted in this work.
In silico epitope prediction and HLA distribution analysis of HTLV-I 1516
JBUON 2018; 23(5): 1516
sure the generation of T-cell immune response. The 
different HLA alleles have varying peptide bind-
ing specificity among ethnic populations. It has 
been reported that only few HLA supertypes can 
cover the majority of alleles, where diverse mem-
bers of a supertype bind similar peptides; these 
similar peptides are called super antigens. Recent-
ly, eighteen major HLA class I supertypes (HLA- 
HLA- A*0101, A*03:01, A*26:01, A*02:01, A*11:01, 
A*68:01, B*08:01, B*37:01, B*07:02, B*14:02, 
B*27:05, B*38:01, B*39:01, B*40:02, B*44:02, 
B*48:01, B*49:01, B*51:01,) and six HLA class II su-
pertypes (DRB1*01:01, DRB1*03:01, DRB1*04:01, 
DRB1*07:01, DRB1*07:07, DRB1*15:01) have been 
determined by comparing peptide-binding data 
[17]. The problem of HLA allele’s population cov-
erage and the chance of antigen escape due to anti-
genic drift or shift may be overcome by the binding 
of peptides exhibiting super antigenic property to 
a maximum number of HLA alleles with their con-
served nature. 
 The present study has been designed for a me-
ticulous analysis of predicted HLA binding pep-
tides of HTLV-1 viral proteins of all the isolates. 
The schematic diagram of the entire methodology 
adopted in this work has been given in Figure 1.
Methods
Retrieval of protein sequences 
 The protein sequence ODS of Envelop glycoprotein 
of six strains of Human T Lymphotropic Virus-I: Japan 
MT-2 subtype A (ENV_HTL1M Envelope glycoprotein 
gp62, P23064), Carribbea HS-35 subtype A (ENV_HTL1C 
Envelope glycoprotein gp62, P14075), Melanesia mel5 
subtype C (ENV_HTL1L Envelope glycoprotein gp62, 
P0C212), Japan ATK-1 subtype A (ENV_HTL1A Enve-
lope glycoprotein gp62, P03381), Zaire EL subtype B 
(ENV_HTL1F Envelope glycoprotein gp62, Q03817) and 
Caribbea CH subtype A (ENV_HTL1N Envelope glyco-
protein gp62, Q03816) were retrieved from UniProtKB 
Database (www.uniprot.org). The retrieved sequences 
were used for various bioinformatics approaches such 
as 3D-structure prediction, antigenicity assessment, and 
epitope prediction. 
Immunogenicity prediction of viral protein and structural 
analysis
 An antigen, which can be recognized by the im-
mune system is called Immunogenic. VaxiJen v2.0 
server [18] (http://www.ddg-pharmfac.net/vaxijen/Vaxi-
Jen/VaxiJen.html) was used for analyzing ‘Env’ protein 
immunogenicity of HTLV-1 of all the genotypes from 
different geographical areas by finding the best potential 
candidate immunogen epitope. VaxiJen is a web server 
to predict the protective antigens, tumor antigens and 
subunit vaccines, with an accuracy of approximately 70 
to 89% for the discrimination between antigens and non-
antigens [18]. The server is based on Auto Cross Covari-
ance (ACC) conversion of protein sequences into uniform 
vectors of principal amino acid properties. It is being 
considered as the first server predicting the protective 
antigens in an alignment-independent manner.
 The crystal or NMR structure of viral envelop pro-
tein was not available in Protein Data Bank (PDB), thus 
selected sequences (from UniProtKB Database) were 
used to develop the three-dimensional (3D) structure. 
In order to build the 3D model, I-TASSER online server 
[19] was used, which employs a fragment based method 
for the modeling of the protein structure. The server pre-
dicted five models along with their C-score. The models 
with highest C-score value, which is directly propor-
tional to the confidence level of the model were selected. 
The modeled structures were validated by the approach 
of Ramachandran Plot using RAMPAGE [20]. Further-
more, the generated model was submitted to ModRe-
finer for atomic level high resolution protein structure 
refinement.
Multiple sequence alignment
 Using ClustalW (www.ebi.ac.uk/clustalw) multiple 
sequence alignment program, best match (conserved 
regions) for the selected sequences were calculated. 
ClustalW is a multiple sequence alignment program 
for DNA or Proteins. It calculates the best matches for 
the selected sequences & arranges them in order of the 
identities, similarities & differences seen.
Epitope prediction
Humoral immunity associated epitope prediction
 For all of the six strains of HTLV-I, B-cell epitopes 
were predicted using ABCPred online server (www.
imtech.res.in/abcpred), selecting the threshold 1.0 and 
window length 20. The server is based on information-
processing paradigm “neural network” inspired by 
the mammalian brain. All the predicted epitopes were 
ranked as per their respective scores. Higher score of 
the peptides depicted the greater probability to be the 
most suitable (immunogenic) epitope for the human 
B-Lymphocytes.
CD4+ and CD8+ epitope prediction
 The peptides capable of stimulating T-cell epitopes 
bind to MHC molecules. Most important attribute of 
MHC molecules is their allelic polymorphism. The Im-
MunoGeneTics/HLA (IMGT) database listed 3,411 hu-
man leukocyte antigens (HLA) class-I and 1,222 HLA 
class II molecules in July 2010 [21]. 
 Envelop protein sequences of all the six strains 
were analyzed for the screening of possible dominant 
T cell epitopes using immunoinformatics tool IEDB on-
line server (www.iedb.org). MHC-I binding and MHC-II 
binding resources available in IEDB were used for the 
binding analysis of all the possible peptides of 18 class 
I HLA alleles: A*0101, HLA-A*03:01, A*26:01, A*02:01, 
A*11:01, A*68:01, B*08:01, B*37:01, B*07:02, B*14:02, 
B*27:05, B*38:01, B*39:01, B*40:02, B*44:02, B*48:01, 
B*49:01, B*51:01, and 6 class II HLA alleles: DRB1*01:01, 
In silico epitope prediction and HLA distribution analysis of HTLV-I 1517
JBUON 2018; 23(5): 1517
DRB1*03:01, DRB1*04:01, DRB1*07:01, DRB1*07:07, 
DRB1*15:01 described earlier [17]. 
 The peptide length was set 10 and 15 for MHC-I 
and MHC-II, respectively. Default IEDB recommended 
prediction method was selected as this selection tries 
to use the best possible method that combines the pre-
dictions from ANN, SMM, and CombLib. The epitopes 
are predicted on the basis of percentile rank; the low 
percentile rank, the high binding affinity.
HLA distribution analysis
 The analysis of population coverage in the context 
of MHC polymorphism becomes typical as different HLA 
types are expressed at considerably different frequencies 
in different ethnicities. Due to the MHC dependence of 
T-cell response, the peptides with more different HLA 
binding specificities result in more population coverage 
in the geographical regions, where the peptide-based 
vaccine might be employed. The population coverage 
rate of the epitopes was calculated using the IEDB pop-
ulation coverage tool (http://tools.immuneepitope.org/
tools/ population/iedb_input) [22]. Each epitope with its 
binding HLA alleles was added, and different geographic 
areas were also included in the analysis.
Peptide modelling
 B-cell and T-cell epitopes were designed using the 
program Discovery Studio 2.5. It was developed and dis-
tributed by Accelrys, USA. Discovery Studio is a software 
suite that has been frequently used to analyze and model 
molecular structures, sequences, and other information 
relevant to life science researchers. It includes utility 
for viewing and editing the data along with the tools for 
conducting the basic data analysis.
Protein-peptide interaction 
 Docking analyses between receptor (human HSPG) 
and T-cell epitopes (predicted through IEDB) were per-
formed using ZDOCK online server having great predic-
tion abilities in Critical Assessment of Predicted Inter-
actions (CAPRI). ZDOCK is authored & maintained by 
ZLAB (Zhipping Weng’s Lab). It is a rigid-body molecular 
docking program based on Fast Fourier Transform algo-
rithm. It analyses all the possible binding modes in the 
translational and rotational space between the two pro-
teins and evaluates each pose on the basis of an energy-
based scoring function. The resulting z-scores with high-
est value were used as appropriate conformational pose. 
Antigenicity of identified epitopes
 Both B-cell and T-cell predicted epitopes were 
checked for their immunogenicity using VexiJen v2.0 
online server (http://www.ddg-pharmfac.net/vaxijen/
VaxiJen/VaxiJen.html).
Epitope physio-chemical property calculations
 Peptide Property Calculator (https://www.genscript.
com) server was used to determine the best solvent for 
the predicted peptide. The working methodology of this 
server is based on its (peptide’s) amino acid sequence.
Virtual scanning of toxic/non-toxic peptides and allergenic-
ity assessment
 The final epitope set was submitted to ToxinPred 
server to identify the toxic/non-toxic peptides. This 
server predicts the toxicity along with all the impor-
tant physio-chemical properties. A quantitative matrix 
was generated on the basis of probability or frequency 
of amino acid at a particular position. The performance 
was assessed by using 5-folds cross validation technique. 
Further, the AllerHunter server was employed to ana-
lyze the allergenicity of the epitopes (http://tiger.dbs.
nus.edu.sg/AllerHunter). AllerHunter is a support vector 
machine (SVM)-pair wise system that assesses the al-
Strain UniProt ID Threshold Overall antigen prediction Antigen
Japan MT-2 subtype A P23064 0.4 0.5004 Probable-Antigen
Caribbea HS-35 subtype A P14075 0.4 0.5161 Probable-Antigen
Melanesia mel5 subtype C P0C212 0.4 0.5015 Probable-Antigen
Japan ATK-1 subtype A P03381 0.4 0.4928 Probable-Antigen
Zaire EL subtype B Q03817 0.4 0.4830 Probable-Antigen
Caribbea CH subtype A Q03816 0.4 0.4978 Probable-Antigen

















Table 2. Score obtained through alignment of sequences
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Figure 2. Structural validation of modeled protein using RAMPAGE: (A) Human HSPG, (B) Japan MT-2, (C) Caribbea 
HS-35, (D) Malensia Mel5, (E) Japan ATK-1, (F) Zaire EL, (G) Caribbea CH.
Protein Ramachandran plot statistics
% residues in most favored regions % residues in allowed regions % residues in outlier regions
Human HSPG 91.5 6.5 2.0
Japan MT-2 94.2 4.9 0.8
Caribbea HS-35 92.2 6.2 1.6
Malensia Mel5 92.8 5.8 1.4
Japan ATK-1 91.2 7.8 1.0
Zaire EL 93.2 5.4 1.4
Caribbea CH 93.6 4.7 1.6
Table 3. Ramachandran Plot calculation of 3D model of Human receptor and viral protein sequences
In silico epitope prediction and HLA distribution analysis of HTLV-I 1519
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lergenicity and allergic cross-reactivity in the proteins. 
AllerHunter predicts allergens and non-allergens with 
high sensitivity and specificity, without compromising 
the efficiency at the classification of proteins with simi-
lar sequences to known allergens [23].
Results 
Immunogenic protein identification and genetic vari-
ability analysis
 The selection of the immunogen is considered 
as the preliminary step of vaccine development. 
The said selection was performed on the sequences 
of all the isolates retrieved for ‘Env’ protein. The 
results revealed all the isolates to be immunogenic 
(Table 1) and genetically highly conserved (Table 
2). The VaxiJen v2.0 online server was used to de-
termine the immunogenicity of protein on the ba-
sis of overall score produced by the specific protein 
sequence.
Structure validation
 Once the sequences were established as immu-
nogenic, the 3D-structures of ‘Env’ proteins were 
predicted using I-TASSER. The structures were 
further validated with Ramachandran plot analysis 
using ‘RAMPAGE’ as shown in Figure 2 and Table 
3. The I-TASSER modelled structure is depicted in 
Figure 3. 
Identification of humoral immunity associated epitope 
 One of the key steps in epitope-based vaccine 
designing is the prediction and identification of the 
B-cell epitopes in the target antigens. The ABCPred 
Figure 3. 3D structure modeled using I-TASSER and refined by ModRefiner. (A) Human HSPG, (B) Japan MT-2,
(C) Caribbea HS-35, (D) Malensia Mel5, (E) Japan ATK-1, (F) Zaire EL, (G) Caribbea CH.
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database was used to obtain the B-cell epitope can-
didates in the ‘Env’ protein of HTLV-1. Based on 
Artificial Neural Network method of the ABCPred 
server, the number of epitopes identified for differ-
ent isolates were as follows:
 11 potential epitopes for Japan MT-2; 10 po-
tential epitopes for Caribbea HS-35; 11 potential 
epitopes for Malesia mel5; 11 potential epitopes 
for Japan ATK-1; 11 potential epitopes for Zaire EL; 
12 potential epitopes for Caribbea CH.
 Humoral immunity associated epitopes pre-
dicted by ABCpred were in descending order of 
their score, depicting the top scorer at the highest 
point having the best binding affinity. Selecting the 
first (top) epitope for each strain has given a total 
of six epitopes. Out of the 6 B-cell epitopes, 5 had 
100% sequence conservation. Therefore, a total of 
two B-cell epitopes “PSQLPPTAPPLLPHSNLDHI” 
and “EPSQLPPTTPPLLPHSNLDH” with score 1 at 
position 180 and 179, respectively, showing high-
est probability to be as antigenic determinants, 
were identified.
Identification of CD4+ and CD8+ epitope 
 MHC-II restricted CD4+ T-cells activation 
plays an important role for initiating and uphold-
ing a proficient antibody response or Cytotoxic T 
Lymphocytes (CTL) response. On the other hand, 
MHC-I restricted CD8+ CTLs has a vital role in 
combating the viral infection. Thus, comprehend-
ing the principles of T cell activation and epitope-
based vaccine design directs the identification of 
helper T-cell epitopes & CTL epitopes. Hence, the 
helper T-cell epitopes & CTL epitopes in the ‘Env’ 
protein of HTLV-1 were identified using in silico 
approach. Here, the immunogenic peptides, ob-
tained with recommended methods were ranked 
according to their consensus percentile rank from 
SWISS-PROT proteins. The lowest percentile rank 
demonstrated the best binders. Selecting the first 
(lowest percentile rank) epitope for each of the 6 
alleles of MHC CLASS II and 18 alleles of MHC 
CLASS I has given 6 helper T-cell epitopes and 18 
CTL epitopes for each of the six strains of HTLV-I 
using IEDB.
Strain Coverage, % Average hit PC90 
Japan MT-2 subtype A 95.15 2.21 1.23
Caribbea HS-35 subtype A 96.41 2.39 1.35
Melanesia mel5 subtype C 96.41 2.39 1.35
Japan ATK-1 subtype A 96.41 2.39 1.35
Zaire EL subtype B 96.41 2.39 1.35
Caribbea CH subtype A 96.41 2.39 1.35
Table 4. HLA distribution and population coverage analysis results
Figure 4. Graphical representation of predicted epitope / HLA distribution among different isolates of HTLV-I.
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S. No. Epitope Z dock-Score Intermolecular Hydrogen Bond Hydrogen Bond Distance
CLASS II (CD4+)
1 LVALLLLVILAGPCI 1579.921 :LEU79:N - A:GLY12:O 3.16958
2 SSPYWKFQHDVNFTQ 1662.858 :ALA4:N - A:SER2:OG 2.15667
:TRP5:N - A:SER2:OG 2.72544
A:SER1:N - :ARG3:O 3.09156
A:SER2:N - :ARG2:O 2.7973
A:SER2:N - :ARG3:O 2.05351
A:SER2:OG - :ARG2:O 3.05556
A:SER2:OG - :ARG3:O 2.37172
A:ASN12:N - :GLU126:OE1 2.85617
A:ASN12:N - :GLU126:OE2 2.95054
3 YWKFQQDVNFTQEVS 1612.931 :TYR44:OH - A:ASP7:O 2.35794
:THR80:N - A:THR11:OG1 1.87384
:GLY182:N - A:TRP2:O 3.05172
:SER188:N - A:PHE4:O 2.76898
:SER188:OG - A:PHE4:O 2.88083
A:VAL1:N - :ASP180:OD1 1.17792
A:TRP2:N - :ASP180:OD2 2.92515
A:TRP2:NE1 - :MET171:O 2.1366
A:TRP2:NE1 - :ARG172:O 2.99427
A:TRP2:NE1 - :LYS173:O 3.124
A:LYS3:NZ - :GLU183:OE2 1.74793
A:GLN5:N - :SER188:OG 2.71964
A:VAL8:N - :TYR44:OH 3.07846
A:THR11:OG1 - :LEU79:O 2.5652
A:THR11:OG1 - :THR80:O 2.94651
4 YSSYHATYSLYLFPH 1874.750 A:THR7:N - :ASP48:OD1 2.26765
A:TYR8:N - :ASP48:OD1 2.16293
A:TYR8:OH - :ARG72:O 2.75544
A:SER9:N - :ASP47:OD2 2.46973
A:SER9:OG - :ASP47:OD1 2.3081
A:SER9:OG - :ASP47:OD2 1.82501
A:TYR11:OH - :TYR191:O 3.02424
5 PCPNLVAYSSYHATY 1607.413 :MET1:N - A:LEU5:O 3.18292
:TRP5:NE1 - A:SER7:OG 1.98532
:TRP5:NE1 - A:SER7:O 2.92805
:TYR44:OH - A:HIS12:O 3.13358
:GLY156:N - A:SER10:OG 2.83934
A:LEU5:N - :SER103:O 2.91771
A:SER10:OG - :ILE155:O 2.01553
A:HIS12:N - :TYR44:OH 3.06947
A:ALA13:N - :TYR44:OH 2.5348
Continued on the next page
Table 5. HSPG-peptide docking results
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Population coverage of epitopes
 HLA allocation varies among the diverse eth-
nic groups and geographic regions around the 
world. Thus, while designing an effective vaccine, 
population coverage must be taken into account to 
cover the maximum possible populations [24]. All 
the alleles in the supplementary data were identi-
fied as the best binders with the predicted epitopes 
and were used to establish the population cover-
age for these epitopes (Figure 4). Almost complete 
population coverage was found for all the puta-
tive helper T-cell epitopes and CTL epitopes in six 
specified geographic regions of the world (Table 4).
Protein peptide docking and CD4+ and CD8+ epitope 
screening 
 When selected CD4+ and CD8+ epitope (best five 
based on best binding affinity; high energy score, 
between receptor and epitope) for all the six strains 
of HTLV-I, were analyzed, we found that several of 
these epitopes had 100% sequence identity. Hence, 
based on the sequence conservation, a total of eight 
domains (five CD4+ & three CD8+) were screened 
out to be used as helper T-cell epitopes: “YSSYHAT-
YSLYLFPH”, “PCPNLVAYSSYHATY”, “YWKFQQD-
VNFTQEVS”, “SSPYWKFQHDVNFTQ”, “LVALLLL-
VILAGPCI”, and CTL epitopes: “SLYLFPHWIK”,
S. No. Epitope Z dock-Score Intermolecular Hydrogen Bond Hydrogen Bond Distance
CLASS I (CD8+)
6 SLYLFPHWIK 1666.732 :LEU79:N - A:LYS10:O 2.39997
:TYR131:OH - A:LEU2:O 2.40817
:THR196:OG1 - A:LEU4:O 2.22273
:LYS197:N - A:TYR3:OH 2.85881
:LYS197:N - A:LEU4:O 2.95916
:GLU198:N - A:LEU4:O 2.28237
A:TYR3:N - :TYR131:OH 1.21732
A:TYR3:OH - :LYS197:O 2.9753
A:PHE5:N - :GLU198:OE2 2.60355
A:HIS7:N - :GLY153:O 2.41912
A:TRP8:NE1 - :GLY156:O 3.12138
7 LHFSKCGFPF 1671.469 :TYR44:OH - A:PHE3:O 2.54674
:SER178:OG - A:PHE10:O 2.77812
:SER178:OG - A:PHE10:OXT 1.86774
:ASP180:N - A:PHE10:O 2.83619
:SER188:OG - A:CYS6:SG 2.50789
A:SER4:N - :TYR44:OH 2.76142
A:CYS6:SG - :SER188:OG 2.50789
A:PHE10:N - :MET171:O 2.943
A:PHE10:N - :TYR179:O 2.46562
A:PHE10:N - :ASP180:OD2 1.70985
8 YHATYSLYLF 1715.898 :MET1:N - A:HIS2:O 2.22991
:TRP5:NE1 - A:THR4:O 1.93176
:TYR44:OH - A:LEU9:O 3.09167
:THR101:OG1 - A:TYR1:OH 2.18107
A:TYR1:OH - :THR101:OG1 2.18107
A:LEU9:N - :TYR44:OH 2.64379
A:PHE10:N - :TYR44:OH 2.19778
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“LHFSKCGFPF”, and “YHATYSLYLF”, which may 
serve as useful diagnostic reagents for evaluating 
immune response against all the strains of HTLV-I 
(Figure 5 and Table 5).
 Further, the peptides with strong antigenicity 
are more likely to be B-cell & T-cell epitopes than 
those with weak antigenicity. Hence, VaxiJen v 2.0 
server (http://www.ddg-pharmfac.net/vaxijen/Vaxi-
Jen/VaxiJen.html) was used to predict the antigenic-
ity of the selected epitopes. This tool predicts the 
antigenicity of a peptide on the basis of amino acid 
properties and their positions in the peptide [18]. 
 The obtained results showed that both the 
predicted B-cell epitopes had antigenic properties 
and they can be crucial in eliciting the desired im-
mune response, whereas, out of the predicted 8 T-
cell epitopes, 5 (four for CD4+ and one for CD8+) 
were found to be probable antigen (Tables 6 and 7).
Figure 5. Docked (Peptide-HSPG) structures generated through Discovery Studio 2.5. Epitopes having best binding 
affinity (highest Z-dock-score) docked with HSPG. (A) LVALLLLVILAGPCI-HSPG, (B) SSPYWKFQHDVNFTQ-HSPG, (C) 
YWKFQQDVNFTQEVS-HSPG, (D) YSSYHATYSLYLFPH-HSPG, (E) PCPNLVAYSSYHATY-HSPG, (F) SLYLFPHWIK-HSPG, 
(G) LHFSKCGFPF-HSPG, (H) YHATYSLYLF-HSPG
Position Humoral associated epitope Antigenic score Antigen/Non-antigen
180 PSQLPPTAPPLLPHSNLDHI 0.5190 Antigen
179 EPSQLPPTTPPLLPHSNLDH 0.4374 Antigen
Table 6. Humoral immunity associated epitope with their antigenic score
Position Allele CD4+ and CD8+ epitope Antigenic score Antigen/ Non-antigen
CD4+ (CLASS II)
449-463 HLA-DRB1*01:01 LVALLLLVILAGPCI 0.3352 Non-Antigen
129-143 HLA-DRB1*04:01 SSPYWKFQHDVNFTQ 0.8936 Antigen
132-146 HLA-DRB1*04:01 YWKFQQDVNFTQEVS 0.7403 Antigen
73-87 HLA-DRB1*07:07 YSSYHATYSLYLFPH 0.5073 Antigen
66-80 HLA-DRB1*15:01 PCPNLVAYSSYHATY 0.9356 Antigen
CD8+ (CLASS I)
81-90 HLA-A*03:01 SLYLFPHWIK -0.0424 Non-Antigen
152-161 HLA-B*14:02 LHFSKCGFPF 0.1898 Non-Antigen
76-85 HLA-B*38:01 YHATYSLYLF 0.5075 Antigen
Table 7. CD4+ and CD8+ epitope with their antigenic score
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Among them, the highest scored antigenic 
epitopes for humoral immunity associated 
and CD4+ and CD8+ (MHC-II & MHC-I) were 
PSQLPPTAPPLLPHSNLDHI, PCPNLVAYSSYHATY 
and YHATYSLYLF, respectively.
Physio-chemical properties of final epitope set
 The overall interactive property calcula-
tion (Table 8) of most antigenic epitopes re-
vealed that highest scored antigenic epitopes 
PSQLPPTAPLLPHSNLDHI, PCPNLVAYSSYHATY 
and YHATYSLYLF, were all suitable to dispense 
in the basic medium, thus, predicted antigenic 
epitopes (BASIC), solubilized in 10% or higher ace-
tic acid solution or by adding <50 μl trifluoroacetic 
acid (TFA) and diluted to 1 ml with deionized water. 
This information can be used to make suitable dilu-
ent for their efficient use as peptide vaccine.
Toxicity and allergenicity screening of the identified 
epitopes
 The final epitope set (CD4+, CD8+ and humoral 
associated) with best antigenic score were further 
confirmed for their toxicity. The obtained results 
are shown in Table 9. Analysis revealed that among 
the best antigenic peptides none (epitopes) were 
found allergic against humans.
Discussion 
 HTLV-I is an infectious virus and causes sev-
eral pathogenic conditions including fatal T-cell 
lymphoma. Recent studies have reported that the 
entry of HTLV-I in humans is mediated by the at-
tachment of the viral envelope (gp46) to the human 
receptor HSPG. Latest advancements in the field 
of bioinformatics have allowed the application of 
immunomics as an alternative approach to the tra-
ditional vaccine development strategy. The online 
accessibility of the complete genome sequences 
has transformed the approach to in silico vaccine 
development. T lymphocytes are crucial in elicit-
ing a protective immune response against various 
microbial infections, thus the identification and 
selection of T-cell epitopes as vaccine targets is a 
prerequisite task for designing the epitope-based 
vaccines. The determination of B-cell epitopes is a 
crucial task for the vaccine development as well as 
for better diagnosis. Recently, synthetic peptides 
have been shown to induce antibodies reactive with 
their associated sequences in the native proteins. 
 As a first step in defining the B- and T-cell 
epitopes in HTLV-I, the search of RCSB Protein 
Data Bank (http://www.rcsb.org) verified that the re-
quired tertiary structures of human protein HSPG 
Peptide sequence SVM score Toxicity prediction Hydrophobicity Hydropathicity
PCPNLVAYSSYHATY
(CD4+ epitope)
-0.64 Non-Toxin -0.01 -0.13
YHATYSLYLF
(CD8+ epitope)
-1.03 Non-Toxin 0.10 0.33
PSQLPPTAPPLLPHSNLDHI
(Humoral associated epitope)
-1.36 Non-Toxin -0.04 -0.37
Table 9. Toxicity analysis of predicted best antigenic epitope set
Epitopes Chemical formula M. Wt Iso-Electric point Hydrophilicity analysis
Charge Attribute
Humoral immunity associated
PSQLPPTAPPLLPHSNLDHI C98H154N26O28 2144.44 6.50 1 Basic
EPSQLPPTTPPLLPHSNLDH C98H152N26O31 2190.42 5.30 0 Neutral
CD8+
YHATYSLYLF C64H84N12O16 1277.43 7.53 1 Basic
CD4+
SSPYWKFQHDVNFTQ C88H118N22O25 1884.02 7.54 1 Basic
YWKFQQDVNFTQEVS C89H123N21O27 1919.06 4.19 -1 Acidic
YSSYHATYSLYLFPH C90H117N19O24 1849.01 7.68 2 Basic
PCPNLVAYSSYHATY C77H108N18O24S1 1701.86 7.34 1 Basic
Table 8. Analysis of Epitope Physio-Chemical property calculation 
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and ‘Env’ protein of HTLV-I was not publicly avail-
able. The FASTA format amino acid sequences of 
the above mentioned proteins were retrieved from 
UniProt (http://www.uniprot.org).
 The immunogenicity of each strain of HTLV-
I was confirmed with the help of Vaxijen online 
server. The alignment of the amino acid sequences 
among six strains of HTLV-I revealed the overall 
identity of the structural proteins (among the iso-
lates, ‘Env’ proteins are known to be genetically 
highly conserved). Following the antigenicity con-
firmation, I-TASSER was employed to predict the 
3D-structure. The refinement of the generated mod-
el was performed by using ModRefiner followed 
by the structure validation by using RAMPAGE. 
The predicted 3D-structures provided more insight 
in comprehending the structure and functions of 
the proteins and were found fit for the interaction 
analysis. 
 The candidates for peptide synthesis were de-
rived from the protein sequence with the help of 
predictive computational algorithms and HLA su-
pertypes. Among all the predicted B-cell epitopes, 
selecting first (top) from each strain criterion was 
followed for generating 6 epitopes. Five out of 10 
epitopes were conserved, and finally we had 2 B-
cell epitopes. 
 Helper T-cell epitopes are crucial for effec-
tive humoral and CTL responses. Although, the 
response to T-cell epitope is dependent upon HLA 
proteins, yet the fact is that HLA is highly polymor-
phic in various ethnic populations. Hence, the HLA 
specificity of T-cell epitopes must be the principal 
criterion for screening of the epitopes as vaccine 
candidates to cover the genetically diverse human 
population [25,26]. The HLA supertype concept has 
a substantial role in the understanding of CD4+ 
and CD8+ epitope’s selection, discrimination dur-
ing T-cell mediated immune response and degen-
eration. In the HLA supertype analysis, IEDB web 
server was used to check the binding of the best 
epitopes with those of HLA alleles; and 18 MHC-I 
and 6 MHC-II peptides were found in all the known 
genotypes, as it is established that an epitope elic-
its a response only if it is capable of binding a 
MHC molecule in an individual. This phenomenon 
is called as denominated MHC restriction of T-cell 
responses. Including multiple peptides with differ-
ent HLA binding specificities increases the cover-
age of the population targeted by the peptide-based 
vaccines or diagnostics. We have performed HLA 
distribution and population coverage analysis for 
the predicted epitopes that showed 96.41% of the 
projected population coverage with 2.39 average 
numbers of epitope hits/HLA combinations recog-
nized by the population.
 It was found that HLA specific predicted 
docked peptides were highly conserved among the 
six genotypes, hence, resulted a total of 8 (5 CD4+ 
and 3 CD8+) epitopes for all the selected geno-
types. Among all the predicted humoral associated 
epitopes, 2 epitopes “PSQLPPTAPPLLPHSNLDHI” 
and “EPSQLPPTTPPLLPHSNLDH” were found to be 
antigenically effective and among 8 T-cell epitopes, 
5 epitopes i.e., 1 CD8+ “YHATYSLYLF”, and 4 CD4+ 
“SSPYWKFQHDVNFTQ”, “YWKFQQDVNFTQEVS”, 
“YSSYHATYSLYLFPH” and “PCPNLVAYSSYHATY” 
were found to be antigenically effective. Further, 
among these antigenic epitopes, 1 epitope “PCPN-
LVAYSSYHATY” at position 66-80 had the highest 
antigenic score (0.9356) ensuring maximum im-
mune response. 
 Additionally, to check the biocompatibility of the 
best (1 each top scorer from B-cell, MHC-II and MHC-I) 
antigenic epitopes “PSQLPPTAPPLLPHSNLDHI”, 
“PCPNLVAYSSYHATY” and “YHATYSLYLF” were 
tested by Epitope Physio-Chemical property cal-
culator. The analysis revealed that these epitopes 
have basic attributes to dissolve in water and if not 
then in 10% acetic acid; otherwise TFA (<50 μl). 
These properties can be used to make a suitable 
diluent to dispense the peptide vaccine. In order 
to evaluate the toxicity of the final epitope set, we 
employed virtual screening of the peptides using 
ToxinPred server (that uses 5-folds cross valida-
tion technique). The obtained results strongly pre-
dicted that all the three epitopes were non-toxic, 
non-allergic and safe for use. 
 The application of the predicted potential 
epitopes instead of whole protein as a vaccine 
has already been established and currently it is in 
enormous use as the predicted epitopes are fully 
capable of representing the complete antigenicity 
of any protein [27]. Epitope-based vaccines have 
given promising results against the highly infec-
tious diseases such as H1N1, HIV, and Tuberculosis 
[28]. These vaccines have low chance of eliciting 
immune response against the self-antigens, thus 
evade autoimmune response [29]. The conventional 
molecular immunology techniques for the search 
of immunogenic peptide to be used as vaccine can-
didates are exorbitantly time-taking and expensive. 
Therefore, the present in silico study may help out 
the experimental biologists by providing assis-
tance in the rapid screening process to facilitate 
the identification of the probable vaccine candi-
dates. Lately, these computational approaches are 
recently being used by many researchers across 
the globe [30]. In silico approach reported in the 
current study for T-cell epitope prediction and 
population coverage analysis not only reduces the 
cost in an efficient manner, but also the time and 
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efforts invested in the planning and execution of 
the experiments and subsequent development of 
epitope-based vaccines. The application of in silico 
approaches by immunologists has helped to speed-
up the in vitro, in vivo and ex vivo studies by cutting 
down the large epitope dataset to a smaller dataset 
that warrants their experimental validation. 
 In conclusion, genetic variability and HLA 
distribution analysis of HTLV-1 genotypes I, II, 
III, IV, V and VI was done for the broader pop-
ulation coverage of the proposed vaccine. The 
screening of the effective dominant immuno-
gens revealed that the identified epitopes were 
protective immunogens with high conservancy 
and bears potential of inducing both protective 
neutralizing antibodies and T-cell responses. The 
obtained peptides “PSQLPPTAPPLLPHSNLDHI”, 
“PCPNLVAYSSYHATY”, and “YHATYSLYLF” were 
fully conserved among different isolates from far 
and wide separated countries suggesting negligi-
ble antigenic drift in HTLV-1. In conclusion, the 
predicted epitopes are soluble, non-toxic suitable 
candidates for the vaccine development against 
HTLV-1 and warrants for further investigation and 
experimental validation. The prophecies made in 
the current study inferred from the primary amino 
acid sequence from various HTLV-I isolates would 
tremendously help the researchers involved in 
the experimental verification of the immunodom-
inant epitopes that are being considered as the 
fundamental to the understanding of the patho-
biology of HTLV-I and its effective ATL vaccine
development.
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